-
6-7 October: Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element.
-
Evolving Real World Data/Evidence Guidelines and Landscape in China: From Policy to Practice
-
Signal - Episode 5- On-demand until November 30
Join Tom Cassels and Alyssa Jaffe - seasoned venture capital investors with background from the healthcare settings - in discussing the highlights, possible implications and learnings from investment activity for the downstream healthcare decision-making where stakeholders are looking primarily at evidence-based solutions.
-
HEOR Theater - Optimizing Research Using Real-World Data During the COVID-19 Pandemic
11:00AM - 11:45AM EST
-
HEOR Theater - Effect Modification in Network Meta-Analysis: Is Population Adjustment Always the Answer?
12:00PM - 12:45PM EST
-
HEOR Theater - Addressing Prenatal Exposures and Outcomes for Regulatory Requirements Using Real-World Data
1:00PM - 1:45PM EST
-
Health Preferences in HTA: Use of Patient and Public Preferences
-
10 November: Use of Propensity Scores in Observational Studies of Treatment Effects
In observational research, issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities.
-
HEOR Theater - External Control Arms – The Case for a Standardized Lexicon and Toolkit
10:00AM - 10:45AM EST
-
HEOR Theater - Real World Insights into the US COVID-19 Crisis: New Findings from Analyses of Claims Data
11:00AM - 11:45AM EST
-
HEOR Theater - Demonstrating the Value of Vaccines: Global NITAG and HTA Requirements
12:00PM - 12:45PM EST
-
HEOR Theater - External Control Arms Using Real-World Data - Filling a Data Gap
1:00PM - 1:45PM EST
-
Virtual ISPOR Europe 2021-On Demand Until January 2
The conference event will provide dedicated content covering the latest trends and topics in HEOR in the European region and globally in a variety of formats including live programming, virtual poster presentations, networking opportunities, a virtual exhibitor gallery, and more, and will include real-time interaction with presenters via Q&A, and in Discussion Rooms.
-
December 6, 8, and 9, 2021: Budget Impact Analysis II: Applications and Design Issues
This course covers the concrete application of the 6-step approach for developing budget impact analyses and provides hands-on learning with two different budget impact models programmed in Excel. The course will review the basics of budget impact analysis, interpretation of results, simplicity versus accuracy and face validity, and how budget impact analyses are used by payers and other decision makers.
-
Biosimilars' Key Next Steps: What Will the Future Bring?
Biological medicines have changed the course of many complex conditions in disease areas such as rheumatology, gastroenterology and oncology, and they remain a key mainstay in many current and next generation therapies. The success and high prices of these biological medicines however challenge healthcare budgets around the globe. Enhancing competition in the biological medicines market, by the introduction of biosimilars, offers an important opportunity to tackle inefficiencies of healthcare systems by lowering treatment costs, and possibly facilitating better access to biological therapies, especially for patient groups that had limited availability of the originator biological due to cost constraints
-
Improving Performance: Selection and Development of PerfO Assessments to Capture Clinical Benefit: Performance Outcome Assessment Emerging Good Practices Task Force
-
Signal Event- On-Demand until February 28
The ISPOR Signal Series welcomes Judea Pearl, professor of computer science and director of the Cognitive Systems Laboratory, Samueli School of Engineering, UCLA, Los Angeles, CA, USA, the world-renowned computer scientist and philosopher, known for his world leading work on artificial intelligence (AI) and the development of Bayesian networks as well as his theory of causal and counterfactual inference. Dr Pearl will make a presentation on how causal models interact with data and work in scientific applications today, spanning the subjects of selection bias, personalized treatment effect, fusion of data from several sources, and causality in observational studies.
-
Signal Series
Signal—ISPOR’s new signature program—looks beyond today’s linear thinking to explore topics that will shape healthcare decision making over the next decade. Seeking to strengthen strategic foresight and adaptive leadership capacities in the complex world of healthcare, the Signal series focuses on the “big picture,” while also addressing how health economics and outcomes research (HEOR) can best contribute to solving healthcare’s greatest challenges.
-
CHEERS 2022 - Reporting Guidance for Health Economic Evaluation: What It Is and How to Use It
-
February 2-3: Understanding Survival Modeling with Application to HTA